DelRicht Research is proud to showcase the outstanding performance of our investigators and site teams in a pivotal US-based Phase 3 trial evaluating treatment for gout, a form of inflammatory arthritis that affects more than 9 million adults in the U.S. 

Over the course of an 8-month enrollment period, our network not only surpassed its assigned goals but emerged as a top contributor across all participating sites nationwide.

Surpassing Enrollment Expectations

The sponsor’s target for this multi-site study was ambitious: 750 participants enrolled across 100 U.S. locations. DelRicht set an enrollment goal of 120 patients spread across 16 of those sites. By the conclusion of enrollment, our teams more than doubled this commitment, enrolling 297 participants. This achievement represented 248% of our goal and 39.6% of the trial’s entire patient population, underscoring the scale and consistency of our contribution to advancing research in a condition that is one of the leading causes of inflammatory arthritis worldwide.

Performance at the site level was equally impressive. Seven DelRicht locations ranked among the top 10 enrollers overall, while 13 of our 16 sites finished within the study’s top 20. Notably, three of our investigators, Dr. Amy Roberts (Town & Country, MO), Dr. Rachael Holliday (Indianapolis, IN), and Dr. Robert Springer (Atlanta, GA), led enrollment for participants with tophaceous gout, highlighting the network’s ability to deliver results in particularly complex subgroups.

Navigating Operational Complexities

One of the primary hurdles in this study was the high number of required systems and electronic portals. Managing multiple platforms simultaneously presented complexity for sites. DelRicht’s Study Start-Up team proactively addressed this challenge through close coordination between sites and CRAs, timely follow-up, and comprehensive training support. This ensured our sites were activated on schedule, study staff were fully trained, and operational flow remained smooth despite added complexity.

This problem-solving mindset reflects a core strength of our model: the ability to anticipate obstacles and deploy centralized support that allows investigators to focus on patient care and recruitment. By minimizing administrative burden, our teams kept enrollment momentum strong and maintained data quality throughout the trial.

Investigator Leadership and Community Engagement

The success of this trial was driven by the expertise and commitment of our principal investigators, who leveraged trusted community relationships and clinical experience to recruit and retain participants effectively. Each site contributed meaningfully to the collective outcome:

Dr. Matthew Mintz | Rockville, MD
Dr. E. Marshall Newton | Charleston, SC
Dr. Taylor Sanders | Prairieville, LA
Dr. Robert Springer | Atlanta, GA
Dr. Jennifer Zomnir | Prosper, TX
Dr. Sean Kerby | Gulfport, MS
Dr. Patrick Dennis | New Orleans, LA
Dr. Jonathan Jacobs | Overland Park, KS
Dr. Luke Van Kirk | Springfield, MO
Dr. Amy Roberts | Town & Country, MO
Dr. Melita Tate | Tulsa, OK
Dr. Rachael Murphy | Mandeville, LA
Dr. Kymberly Moyer | Hendersonville, TN
Dr. Michael Lovelace | Louisville, KY
Dr. Lisa Larkin | Cincinnati, OH
Dr. Rachael Holliday | Indianapolis, IN

This breadth of participation demonstrates how DelRicht’s embedded model enables us to rapidly mobilize across diverse geographies and patient populations while ensuring consistent execution.

What This Means for Sponsors and CROs

The outcomes of this Phase 3 gout trial reinforce DelRicht’s value as a site network partner:

High-Volume Enrollment: Exceeding expectations with consistent performance across multiple locations.
Operational Agility: Overcoming study complexity through proactive coordination and centralized support.
Investigator Leadership: Trusted physician-investigators engaging patients directly within their communities.
Data Reliability: Driving quality outcomes even in high-barrier indications.

Partner With Us

At DelRicht Research, we don’t just contribute to clinical trials; we help define their success. By combining operational excellence, community-based engagement, and proven investigator leadership, our network delivers meaningful results for sponsors and CROs across therapeutic areas.

Learn more about our capabilities in rheumatology and other specialties at www.DelRichtResearch.com, or connect with us directly to explore partnership opportunities.